InvestorsHub Logo
Followers 26
Posts 165
Boards Moderated 0
Alias Born 12/16/2015

Re: pgsd post# 66194

Wednesday, 07/06/2016 6:54:00 PM

Wednesday, July 06, 2016 6:54:00 PM

Post# of 698574
I saw but didn't read Steve's research report on CYTR posted on Seeking Alpha. I know he believes the aldoxorubicin ph3 study will be a success. I disagree. I think the study will fail.

I don't have any "feelings" about Steve's CYTR call. Did he ridicule me? That doesn't seem like his style but it doesn't really matter. I don't get worked up about people with opposing views on stocks. There's a bull and bear thesis on every stock. That's the way the market works.

If Steve is right about CYTR, i'll congratulate him on making a good call and I'll acknowledge my error. I'm pretty sure he'll do the same if the aldoxorubicin study fails.

I did see that Steve asked me to acknowledge that even with my bearish call on CYTR, it's still better than NWBO.

I see it differently, CYTR = NWBO in that they're both worthless in the end. I don't know how long it will take for both stocks to reach terminal zero, but they will both get there. Perhaps NWBO sooner than CYTR given the former's precarious financial position. This week's financing was truly desperate. NWBO went back to the market on the 45th day and last day of its standstill agreement with the investor in the previous deal. The company was so short of cash that it, literally, could not wait a single day before raising more.

The buyers of this week's deal were PIPE funds, which means they've already sold the stock they bought. They only care about the free warrants.




Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News